Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 4Phase 1 3Phase 2/3 2Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cisplatin 17Magnetic Resonance Spectroscopy 16Specimen Handling 13pembrolizumab 10Carboplatin 10Gemcitabine 9Paclitaxel 8Radiotherapy 7Radiation 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Pemetrexed 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Docetaxel 5Dexamethasone 5Biopsy 5atezolizumab 4Rituximab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4Temozolomide 3Standard of Care 3Ramucirumab 3Drug Therapy 3Cyclophosphamide 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × prednylidene × 30 days × Clear all
NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡